A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
暂无分享,去创建一个
D. Esseltine | S. Jagannath | A. Jakubowiak | S. Lonial | N. Munshi | P. Richardson | C. Mitsiades | J. Feather | N. Raje | T. Hideshima | J. Kaufman | I. Ghobrial | D. Vesole | W. Xie | R. Schlossman | E. Weller | R. Knight | A. Mazumder | M. McKenney | M. Alsina | D. Warren | K. Colson | Dixil Francis | K. Anderson | L. Lunde | Michelle E. Maglio | M. Mckenney
[1] A. Gupta. [Hemoglobin]. , 2018, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.
[2] Michael L. Wang,et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. , 2013, Blood.
[3] M. Beksac,et al. Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma , 2013, Haematologica.
[4] M. Dimopoulos,et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma , 2013, British journal of haematology.
[5] Michael L. Wang,et al. Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma , 2013, Clinical Cancer Research.
[6] R. Greil,et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Trudel,et al. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma , 2013, Leukemia & lymphoma.
[8] H. van de Velde,et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma , 2012, Haematologica.
[9] A. Oriol,et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. , 2012, Blood.
[10] B. Pégourié,et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Anyou Wang,et al. (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials , 2012, Annals of Hematology.
[12] I. Flinn,et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. , 2012, Blood.
[13] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[14] P. Wen,et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012, Leukemia.
[15] C. Chen,et al. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma , 2012, Leukemia.
[16] B. Pégourié,et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. , 2011, Blood.
[17] A. Hui,et al. A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM) , 2011 .
[18] M. Kaminski,et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. , 2011, Blood.
[19] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[20] F. Zhan,et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. , 2011, Clinical lymphoma, myeloma & leukemia.
[21] M. Offidani,et al. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma , 2011, Annals of Hematology.
[22] G. Hess,et al. Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland , 2011, Oncology.
[23] J. Crowley,et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). , 2010, Blood.
[24] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[25] Heinz Ludwig,et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. , 2010, The Lancet. Oncology.
[26] M. Mohty,et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[28] Michael L. Wang,et al. Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD) , 2010, Hematology.
[29] D. Esseltine,et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Robert McDougall Kerr,et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib , 2009, American journal of hematology.
[31] H. Brenner,et al. Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010 , 2008, Haematologica.
[32] D. Esseltine,et al. Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma , 2008, British journal of haematology.
[33] D. Battleman,et al. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. , 2008, Clinical advances in hematology & oncology : H&O.
[34] A. Bosi,et al. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma , 2008, British journal of haematology.
[35] D. Esseltine,et al. Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up , 2008, British journal of haematology.
[36] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[37] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[38] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[39] Anthony Boral,et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.
[40] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[41] D. Esseltine,et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[43] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[44] N. Munshi,et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.
[45] P. Elliott,et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.
[46] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[47] M. Kaminski,et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.
[48] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[49] R. Fonseca,et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.
[50] M. Dimopoulos,et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.
[51] M. Dimopoulos,et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis , 2008, Leukemia.